🔬 Pregnancy Test (Beta-hCG)

A pregnancy test measures the hormone human chorionic gonadotropin (hCG), produced by the syncytiotrophoblast of the placenta. It can be performed as a qualitative urine test for rapid screening or a quantitative blood test for detailed clinical monitoring. It is essential for diagnosing pregnancy, assessing the risk of ectopic pregnancy, and monitoring early pregnancy complications. In clinical practice, any woman of reproductive age presenting with acute abdominal pain is considered 'pregnant until proven otherwise' via this test.

Indications include suspected pregnancy (amenorrhea, nausea, breast tenderness), investigation of acute abdominal or pelvic pain, and management of abnormal vaginal bleeding in women of reproductive age. It is used in the 'Pregnancy of Unknown Location' (PUL) clinical pathway. Additionally, it is indicated for screening prior to prescribing teratogenic medications (e.g., isotretinoin, methotrexate), performing radiological procedures involving ionising radiation, or proceeding with elective surgery. It may also be used as a tumour marker for certain germ cell tumours.

Pregnancy testing detects human chorionic gonadotropin (hCG), specifically the beta subunit to avoid cross-reactivity with LH and FSH. Qualitative testing (Yes/No) is typically performed on urine using lateral flow immunoassays (sensitive to ~25 IU/L). Quantitative testing (numerical value) is performed on venous blood using Enzyme-Linked Immunosorbent Assay (ELISA) or similar laboratory techniques. Blood tests are more sensitive and can detect pregnancy within 6-10 days of conception, often before a missed period.

In a healthy, non-pregnant woman, beta-hCG is typically undetectable or extremely low (<5 IU/L). In the context of a confirmed pregnancy, 'normal' levels depend entirely on gestational age; for example, at 4 weeks LMP, levels are typically 5-425 IU/L, rising to peak at 100,000+ IU/L by the end of the first trimester (roughly 10-12 weeks). After delivery or miscarriage, levels should return to undetectable over several weeks.

Interpretation involves comparing the quantitative level to the estimated date of the last menstrual period (LMP). In a PUL, the 'discriminatory zone' is the hCG level (often 1,500 IU/L) above which an intrauterine pregnancy should be visible on transvaginal ultrasound. If hCG is above this and the uterus is empty, ectopic pregnancy is highly likely. Successive measurements are needed to determine viability; a fall of >50% in 48 hours usually indicates a resolving miscarriage, while a rise of <63% suggests an ectopic or failing pregnancy.

A positive result is defined by a beta-hCG level above the laboratory's specific threshold (usually >5-25 IU/L). For a healthy intrauterine pregnancy, levels should approximately double every 48 hours in the first trimester. Abnormally slow rises or plateaus are associated with ectopic pregnancies or failing early pregnancies (miscarriage). Exceptionally high levels (disproportionate to gestational age) may indicate multiple gestations or gestational trophoblastic disease (e.g., molar pregnancy). Low levels for dates may suggest a non-viable pregnancy.

Beta-hCG is the gold standard for confirmation of pregnancy. In the acute setting, it is the single most important test for any woman of childbearing age presenting with abdominal pain or vaginal bleeding to exclude ectopic pregnancy, which is a life-threatening surgical emergency. It is also used to monitor the resolution of pregnancy tissue after miscarriage or to track response to treatment in molar pregnancy or choriocarcinoma. Pre-operative and pre-radiological screening depends on this test to ensure fetal safety.

A major pitfall is relying on a single hCG value to determine viability; serial testing is almost always required. Another is failing to perform the test in post-menopausal women who may still be at risk, or in young adolescents where pregnancy might be denied. Clinicians should also be wary of 'phantom hCG', where heterophile antibodies in the patient's blood interfere with the assay, giving a false positive; this can be checked by testing the urine (hCG doesn't pass into urine in these cases).

Qualitative urine tests can give false negatives if the urine is overly dilute or if tested too early (before implantation). Quantitative blood tests are highly sensitive but cannot determine the location of the pregnancy in isolation. Very early in pregnancy, single values are difficult to interpret without a serial measurement 48 hours later. Rarely, certain medical conditions (like renal failure or paraneoplastic syndromes) or medications containing hCG (used in IVF) can cause false-positive results. Pituitary hCG in peri-menopausal women can also cause low-level positives.

For the MLA, remember the 'Pregnancy of Unknown Location' (PUL) algorithm. Never discharge a woman with abdominal pain and a positive hCG without a plan for follow-up or scan. Urinary hCG should be the first-line 'stat' test in the Emergency Department for any woman of reproductive age with abdominal symptoms. Be aware of the 'Hook Effect'—extremely high hCG levels (as in molar pregnancy) can occasionally cause a false-negative urine test due to antibody saturation.